Glomerulonephritis
|
The benefits of Wobenzym® in regards
to the treatment of
glomerulonephritis is due to many beneficial actions of
Wobenzym® including among other actions, its antioxidant
effect, its anti-inflammatory functions, and its ability to
restore normal lipid (fats) metabolism. One study concludes
that Wobenzym® is the drug of choice, decreasing the
velocity of kidney destructive processes. Most people are familiar with the concept of “antioxidants”. The reason we take antioxidants is to control the amount of oxidation that takes in cells and tissues. There must be a balance between oxidizing and antioxidazing systems in all tissues. While some oxidation is normal, excessive oxidative stress causes tissues to quit functioning properly, and can even cause cells to die. Increased oxidation is part of the inflammatory process that in glomerulonephritis. Wobenzym® has documented antioxidant properties restores the ability of the kidneys to control excessive oxidations and preserve the health and function of kidney cells and tissues. The anti-inflammatory action of Wobenzym® spare the destruction of tissues cells and proteins, and glycoproteins, including an important protein called fibronectin. Fibronectin is a glycoprotein (a protein like molecule) that has many functions including helping cells stay anchored within the kidney, and is referred to as a “cell adhesion molecule”. Since it helps maintain the structure of tissues, it is a “structural protein”. In chronic glomerulonephritis the kidneys ability to make enough fibronectin to keep the kidney cells in place is impaired. Wobenzym® restores the ability of the body to make this important structural protein by controlling the excessive inflammation that interferes with normal fibronectin production and function. One of the consequences of chronic glomerulonephritis is the development of abnormal blood lipid (fats in the blood) profiles, which cause additional damage to kidney structure and function. Wobenzym® reduced kidney tissue damage and symptoms of abnormal blood lipids. The restoration of normal lipid function has also been noted in atherosclerosis. It is also import to remember that Wobenzym® also decreases circulating levels of anti-tissue antibodies, and circulating immune complexes (CIC), both of which are implicated in the disease processes of glomerulonephritis. From FREQUENTLY ASKED QUESTIONS, with answers by Joseph J Collins, RN, ND Read the special section: KIDNEY AND BLADDER CONDITIONS & WOBENZYM® |
What the literature says about Systemic Enzyme Support and:
Glomerulonephritis
Antioxidant effect of wobenzym applied for patients with chronic
glomerulonephritis
Mukhin IV. [Antioxidant effect of wobenzym
applied for patients with chronic glomerulonephritis] [Article in
Ukrainian] Lik Sprava. 2007
Jan-Mar;(1-2):58-61.
There is formation of free radicals in mesangial cells in patients
with chronic glomerulonephritis which increases destruction of renal
tissue and enable autoimmune inflammation. The unbalance between
activity of oxidizing and antioxidazing starts developing. It
accelerates the progression of the disease. The article presents the
assessment of influence of enzyme medication Wobenzym on main
indices of oxidizing and antioxidazing systems. It was established
the presence of antioxidant effect in Wobenzym medication. The use
of this medication in combination with other drugs and without them
enables restoration of the disturbed balance.
PMID:
17684803
Systemic enzyme therapy of
experimental gout glomerulonephritis
Ignatenko GA, Mukhin IV.
[Systemic enzyme therapy of experimental gout
glomerulonephritis] [Article
in Russian] Patol Fiziol Eksp Ter. 2004 Oct-Dec;(4):26-8.
Renal lesion deteriorates the course and prognosis of gouty
glomerulonephritis. Current pathogenetic therapy is not sufficiently
effective. Effects of different treatments on morphological and
functional manifestations of renal disorders in experimental gouty
glomerulonephritis are reviewed.
PMID:
15568502 (When the MeSH Terms are viewed, we see that Wobenzym®
was used in this study.)
Experimental systemic enzyme
therapy of gouty and primary glomerulonephritis
Mukhin IV, Nikolenko VIu.
[Experimental systemic enzyme therapy of gouty and primary
glomerulonephritis] [Article in Russian] Department of Pharmacology,
Donetsk State Medical University, Prospekt Il'icha 16, 34000
Donetsk, Ukraine. Eksp Klin Farmakol. 2003 Jul-Aug;66(4):32-5.
The influence of a systemic enzymotherapy on the morphological,
biochemical, and functional manifestations of the kidney damage
during the experimental gouty and primary glomerulonephritis is
described in comparison to the results obtained by traditional
methods.
PMID:
14558349 (When the MeSH Terms are viewed, we see that Wobenzym®
was used in this study.)
Treatment of dyslipoproteinemia by systemic enzyme therapy in
experimental glomerulonephritis
Mukhin IV.
[Treatment of dyslipoproteinemia by systemic enzyme therapy in
experimental glomerulonephritis] [Article in Russian] Patol Fiziol
Eksp Ter. 2002 Oct-Dec;(4):27-8.
Patients with chronic glomerulonephritis (CG) develop disturbances
of lipid blood spectrum leading to additional damage to renal
structure. The existent methods of pathogenetic therapy have no
effect on lipid imbalance. Recently, many autoimmune diseases have
been treated with systemic enzyme therapy (SET). The authors studied
SET effect in disturbed lipid metabolism in experimental
glomerulonephritis. Experimental animals showed morphological and
biochemical changes similar to those in CG of man. SET reduced renal
tissue damage and symptoms of dyslipoproteinemia.
PMID:
12638428 (When the MeSH Terms are viewed, we see that Wobenzym®
was used in this study.)
Fibronectin content in the
urine of patients with chronic glomerulonephritis as a test for the
efficiency of treatment
Mukhin IV.
[Fibronectin content in the urine of patients with chronic
glomerulonephritis as a test for the efficiency of treatment]
[Article in Russian] Klin Lab Diagn. 2001 Apr;(4):53-5.
Renal fibronectin synthesis is impaired in patients with chronic
glomerulonephritis. We measured urinary fibronectin for evaluating
the efficiency of various methods of treatment. Traditional therapy
of patients with the nephrotic syndrome at the stage of renal
failure leads to decrease of fibronectinuria, which can be
indicative of the progress of nephrosclerotic process in the renal
parenchyma; monotherapy with Wobenzym during the azothemic stage of
disease in patients with the urinary and nephrotic syndrome does not
cause statistically significant changes in the level of urinary
fibronectin, which can be regarded as inhibition of nephrosclerosis
process. Hence, Wobenzym is
the drug of choice, decreasing the velocity of nephrosclerotic
processes, when pathogenetic therapy is largely limited or precluded.
Combination of wobenzyme with pathogenetic drugs in patients with
the nephrotic syndrome and intact renal function suppresses
fibronectinuria due to mutual potentiation of the antiinflammatory
effect. Decrease of fibronectin concentration in the urine after
wobenzyme monotherapy in patients with the urinary syndrome without
signs of chronic renal insufficiency confirms the antiinflammatory
effect of the drug.
PMID:
11393035 (When the MeSH Terms are viewed, we see that Wobenzym®
was used in this study.)